CA2224646A1 - Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante - Google Patents
Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante Download PDFInfo
- Publication number
- CA2224646A1 CA2224646A1 CA002224646A CA2224646A CA2224646A1 CA 2224646 A1 CA2224646 A1 CA 2224646A1 CA 002224646 A CA002224646 A CA 002224646A CA 2224646 A CA2224646 A CA 2224646A CA 2224646 A1 CA2224646 A1 CA 2224646A1
- Authority
- CA
- Canada
- Prior art keywords
- leptin
- chimera
- human
- variant
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title claims abstract description 37
- 229940039781 leptin Drugs 0.000 title claims abstract description 35
- 102000016267 Leptin Human genes 0.000 title claims abstract description 32
- 108010092277 Leptin Proteins 0.000 title claims abstract description 32
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 14
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 14
- 208000008589 Obesity Diseases 0.000 claims abstract description 20
- 235000020824 obesity Nutrition 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 108020004414 DNA Proteins 0.000 claims description 50
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 22
- 102000053602 DNA Human genes 0.000 claims description 21
- 239000002537 cosmetic Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 101001063991 Homo sapiens Leptin Proteins 0.000 claims description 8
- 102000049953 human LEP Human genes 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 36
- 102000004169 proteins and genes Human genes 0.000 abstract description 22
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 7
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 5
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000037432 silent mutation Effects 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- -1 MnC12 Chemical compound 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001069925 Orestes Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne de la leptine chimérisée, à savoir des protéines comprenant de la leptine, l'un de ses mutants, ou l'une de ses variantes, fusionnées à un domaine d'immunoglobuline humaine. L'un des domaines préférés d'immunoglobuline est le domaine Fc de l'immunoglobuline humaine. Malgré leur grande taille moléculaire, ces dérivés chimériques de la leptine présentent une bonne activité pharmacologique combinée à des durées élevées d'élimination par l'organisme. Ces dérivés de leptine conviennent donc particulièrement pour le traitement ou la prophylaxie de l'obésité ou des affections et états associés à l'obésité tels que l'athérosclérose, l'hypertension et le diabète de type II.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9511935.0 | 1995-06-13 | ||
| GBGB9511935.0A GB9511935D0 (en) | 1995-06-13 | 1995-06-13 | Novel compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2224646A1 true CA2224646A1 (fr) | 1997-01-03 |
Family
ID=10775951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002224646A Abandoned CA2224646A1 (fr) | 1995-06-13 | 1996-06-11 | Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0832219A2 (fr) |
| JP (1) | JPH11507547A (fr) |
| AU (1) | AU6011096A (fr) |
| CA (1) | CA2224646A1 (fr) |
| GB (1) | GB9511935D0 (fr) |
| WO (1) | WO1997000319A2 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112659B2 (en) | 1995-11-22 | 2006-09-26 | Amgen, Inc. | OB fusion protein compositions and methods |
| US7208577B2 (en) | 1995-11-22 | 2007-04-24 | Amgen, Inc. | Methods of increasing lean tissue mass using OB protein compositions |
| US7524937B2 (en) | 1996-01-08 | 2009-04-28 | Genentech, Inc. | WSX receptor agonist antibodies |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310034B1 (en) | 1993-05-21 | 2001-10-30 | Ut-Battelle, Llc | Agouti polypeptide compositions |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| ES2217327T3 (es) * | 1995-11-22 | 2004-11-01 | Amgen Inc., | Proteina ob para aumentar la masa de tejido magro. |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| RU2178307C2 (ru) * | 1995-12-27 | 2002-01-20 | Джинентех Инк. | Производные ов-протеина |
| AU769250B2 (en) * | 1995-12-27 | 2004-01-22 | Genentech Inc. | OB protein derivatives having prolonged half-life |
| US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
| US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
| AU770897B2 (en) * | 1996-12-20 | 2004-03-04 | Amgen, Inc. | OB fusion protein compositions and methods |
| EA004790B1 (ru) * | 1996-12-20 | 2004-08-26 | Амген Инк. | Композиции на основе слитого белка ов и способы их применения |
| EP0991419A1 (fr) * | 1997-02-25 | 2000-04-12 | Eli Lilly And Company | Traitement de l'infertilite au moyen de ligands des recepteurs de leptine |
| US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
| AU2002300605B8 (en) * | 1997-04-17 | 2006-02-09 | Amgen Inc. | Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods |
| CA2286098C (fr) * | 1997-04-17 | 2009-07-07 | Amgen Inc. | Compositions comprenant des conjugues de proteine ob humaine, active, stable avec une chaine fc d'anticorps et leurs procedes |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| AU8182298A (en) * | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
| US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
| US6187564B1 (en) | 1997-07-10 | 2001-02-13 | Beth Israel Deaconess Medical Center | DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics |
| BR9908226A (pt) * | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| WO2000007014A2 (fr) | 1998-07-28 | 2000-02-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Induction de genes a mediation par la leptine |
| CN1341121A (zh) * | 1999-01-07 | 2002-03-20 | 利思进药品公司 | 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运 |
| EP1177285A1 (fr) * | 1999-05-07 | 2002-02-06 | Genentech, Inc. | Nouveaux polypeptides d'erythropoietine du chimpanze (chepo) et acides nucleiques codant pour ces memes polypeptides |
| WO2001025428A1 (fr) * | 1999-10-01 | 2001-04-12 | Eli Lilly And Company | Nouvel homologue humain de la leptine |
| JP5179689B2 (ja) * | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| ATE300611T1 (de) | 2000-05-22 | 2005-08-15 | Vlaams Interuniv Inst Biotech | Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen |
| US7235629B2 (en) | 2000-11-14 | 2007-06-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Functional fragment of the leptin receptor |
| US7189830B2 (en) * | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
| DK1641483T3 (da) * | 2003-06-12 | 2008-06-02 | Lilly Co Eli | Fusionsproteiner |
| AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| AU2004282984B2 (en) | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
| US8420087B2 (en) | 2004-01-05 | 2013-04-16 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| US7423113B2 (en) | 2004-08-25 | 2008-09-09 | Vib Vzw | Leptin antagonist |
| WO2006053883A1 (fr) | 2004-11-18 | 2006-05-26 | Vib Vzw | Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine |
| CA2589647A1 (fr) * | 2004-12-22 | 2006-06-29 | Eli Lilly And Company | Preparations contenant une proteine hybride analogue du glp-1 |
| EP2441838A3 (fr) * | 2006-01-24 | 2013-07-10 | Domantis Limited | Protéines de fusion contenant des jonctions naturelles |
| KR20120030383A (ko) | 2009-04-22 | 2012-03-28 | 메르크 파텐트 게엠베하 | 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0464533B1 (fr) * | 1990-06-28 | 1998-07-29 | Hoechst Aktiengesellschaft | Protéines fusionnées avec des portions d'immunoglobulines, leurs production et utilisation |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB9509164D0 (en) * | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
| EP0826045A1 (fr) * | 1995-05-08 | 1998-03-04 | Chiron Corporation | Acides nucleiques pour traiter l'obesite |
-
1995
- 1995-06-13 GB GBGB9511935.0A patent/GB9511935D0/en active Pending
-
1996
- 1996-06-11 CA CA002224646A patent/CA2224646A1/fr not_active Abandoned
- 1996-06-11 WO PCT/GB1996/001388 patent/WO1997000319A2/fr not_active Application Discontinuation
- 1996-06-11 JP JP9502784A patent/JPH11507547A/ja active Pending
- 1996-06-11 EP EP96917584A patent/EP0832219A2/fr not_active Withdrawn
- 1996-06-11 AU AU60110/96A patent/AU6011096A/en not_active Abandoned
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112659B2 (en) | 1995-11-22 | 2006-09-26 | Amgen, Inc. | OB fusion protein compositions and methods |
| US7208577B2 (en) | 1995-11-22 | 2007-04-24 | Amgen, Inc. | Methods of increasing lean tissue mass using OB protein compositions |
| US7718400B2 (en) | 1995-11-22 | 2010-05-18 | Amylin Pharmaceuticals, Inc. | Methods of increasing lean tissue mass using OB protein compositions |
| US8080254B2 (en) | 1995-11-22 | 2011-12-20 | Amgen, Inc. | OB fusion protein compositions and methods |
| US7524937B2 (en) | 1996-01-08 | 2009-04-28 | Genentech, Inc. | WSX receptor agonist antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997000319A2 (fr) | 1997-01-03 |
| WO1997000319A3 (fr) | 1997-04-10 |
| AU6011096A (en) | 1997-01-15 |
| EP0832219A2 (fr) | 1998-04-01 |
| GB9511935D0 (en) | 1995-08-09 |
| JPH11507547A (ja) | 1999-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2224646A1 (fr) | Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante | |
| Kim et al. | Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site‐directed mutagenesis | |
| US5932448A (en) | Bispecific antibody heterodimers | |
| KR100391227B1 (ko) | 인체의 프로그램화 된 세포사멸과 관련있는 펩티드 및 이를 암호하는 디엔에이(dna) | |
| KR102219124B1 (ko) | 비글리코실화 Fc-함유 폴리펩티드 | |
| KR100687388B1 (ko) | 인터루킨-18 결합 단백질, 이들의 제조방법 및 용도 | |
| CA2160800C (fr) | Proteines gonadotropes modifiees par l'adjonction de sequences ctp | |
| KR100545720B1 (ko) | 당화된 면역글로불린 및 이를 포함하는 면역접합체 | |
| JPH04502408A (ja) | ＩＬ―２レセプターのｐ５５ Ｔａｃタンパク質に特異的なキメラ免疫グロブリン | |
| JPH08506247A (ja) | 組換えｃｔｌａ４ポリペプチドおよびその製造方法 | |
| PL182665B1 (pl) | Rozpuszczalne białko mające aktywność antagonistyczną lub częściową aktywność antagonistyczną wobec IL4 i/lub IL13, sposób wytwarzania rozpuszczalnego białka, polimer DNA, replikujący wektor ekspresji, komórka gospodarza i środek farmaceutyczny | |
| MXPA05000202A (es) | Cuerpos mimeicos ch1-deletados de epo de mimetica de mamifero. | |
| JP2003514552A (ja) | 改善された性質を有するエリトロポエチンの形態 | |
| JP6114186B2 (ja) | 組換えヒトｇ−ｃｓｆ二量体およびその神経系疾患の治療における用途 | |
| EP0432510B1 (fr) | Procédé pour la préparation de vecteurs génétiques pour l'expression du facteur de croissance des nerfs dans des cellules eucaryotiques | |
| WO1999002709A1 (fr) | Proteines hybrides recombinees d'erythropoietine / immunoglobuline | |
| HUE033298T2 (en) | Fusion polypeptide EB virus-induced tumor and colic and mutant | |
| EP1283217B1 (fr) | Anticorps contre le récepteur d'IL-8 et leurs utilisations thérapeutiques | |
| MX2007000115A (es) | Hoja de puerta de cristal pivotante alrededor de un quicio superior y uno inferior. | |
| CA2339968A1 (fr) | Dcr5, proteine de fixation de proteines morphogenetiques osseuses, et ses applications | |
| EA017377B1 (ru) | Слитый белок эритропоэтина | |
| JPH08507684A (ja) | 腫瘍細胞死誘導法 | |
| JP2004506021A (ja) | Ｔ細胞媒介性病態を改変するための方法および組成物 | |
| WO2023051412A1 (fr) | PROTÉINE DE FUSION β-NGF, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION | |
| AU2140699A (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |